JAK2 V617F Mouse Pathology Testing: Comprehensive Hematological and Histopathological Evaluation

JAK2 V617F mouse pathology testing provides comprehensive histopathological, hematological, and molecular evaluation of mouse models carrying the JAK2 V617F mutation, the hallmark driver lesion of human myeloproliferative neoplasms. This service supports disease phenotyping, mechanism-of-action studies, and preclinical efficacy assessment of JAK inhibitors and other candidate therapeutics. From complete blood counts and bone marrow fibrosis grading to mutant allele burden quantification, standardized pathology workflows deliver reproducible, publication-quality data.

Technical Overview

The JAK2 V617F mutation is a somatic gain-of-function point substitution (c.1849G>T) that converts valine 617 to phenylalanine within the pseudokinase (JH2) domain of Janus kinase 2. This mutation disrupts the autoinhibitory function of the JH2 domain, leading to constitutive activation of JAK-STAT signaling and cytokine-independent proliferation of hematopoietic cells. In humans, JAK2 V617F is present in approximately 95% of polycythemia vera (PV) patients, 55–65% of essential thrombocythemia (ET) patients, and 40–50% of primary myelofibrosis (PMF) patients.

Genetically engineered mouse models carrying JAK2 V617F—including conditional knock-in mice expressing the mutant allele from the endogenous Jak2 locus and transgenic models expressing human JAK2 V617F under hematopoietic promoters—faithfully recapitulate key features of human myeloproliferative neoplasms (MPNs). These mice develop a PV-like disease characterized by erythrocytosis, leukocytosis, splenomegaly, extramedullary hematopoiesis, and progressive myelofibrosis. Systematic pathology testing is therefore essential for confirming genotype-phenotype correlations, monitoring disease progression, and evaluating therapeutic efficacy in preclinical studies.

Typical pathological manifestations observed in JAK2 V617F mice include:

• Elevated red blood cell counts, hematocrit, and hemoglobin consistent with erythrocytosis
• Marked leukocytosis with neutrophilia and variable thrombocytosis
• Progressive splenomegaly with trilineage extramedullary hematopoiesis
• Bone marrow hypercellularity with megakaryocytic hyperplasia and atypical clustering
• Age-dependent reticulin and collagen fibrosis, progressing to osteosclerosis in advanced disease
• Hepatic extramedullary hematopoiesis and portal tract infiltration
• Reduced serum erythropoietin levels due to autonomous erythroid proliferation

Testing Samples

Peripheral Blood

Peripheral blood is collected from the retro-orbital sinus, submandibular vein, or tail vein, typically in EDTA-coated tubes. Samples are used for automated complete blood counts with five-part differential, manual blood smear morphology, plasma isolation for erythropoietin and cytokine measurement, and buffy coat DNA extraction for allele burden analysis. Serial sampling at multiple time points enables longitudinal monitoring of disease burden and drug response.

Bone Marrow

Bone marrow is harvested from femurs, tibias, and iliac crests. One femur is reserved for flow cytometric analysis of hematopoietic stem and progenitor populations, while the contralateral femur and other bones are fixed intact for histomorphological evaluation. Decalcified bone sections allow assessment of cellularity, megakaryocyte number and morphology, reticulin and collagen deposition, and bone remodeling.

Spleen and Liver

The spleen is weighed at necropsy to calculate the spleen-to-body weight ratio, a sensitive quantitative index of extramedullary hematopoiesis. Representative sections from the splenic hilar region are fixed for histology. Liver samples are collected from defined lobes to evaluate sinusoidal and portal extramedullary hematopoiesis, which reflects systemic disease involvement.

Other Organs

Lung, heart, kidney, brain, and gastrointestinal tract are routinely examined for thrombotic or hemorrhagic complications associated with hyperviscosity and platelet dysfunction, as well as for off-target drug toxicity in interventional studies. Gross necropsy observations, organ weights, and standardized tissue collection ensure comprehensive pathological assessment.

Testing Items

Core pathology testing panels for JAK2 V617F mouse models cover hematological, histological, immunophenotypic, and molecular endpoints:

• Complete blood count with differential: red cell parameters (RBC, HGB, HCT, MCV), white cell parameters (WBC, neutrophils, lymphocytes, monocytes), and platelet count
• Blood smear morphological review: polychromasia, teardrop cells, giant platelets, circulating megakaryocyte nuclei, and blast assessment
• Serum biochemistry: erythropoietin, lactate dehydrogenase, and inflammatory cytokine panels
• Organ weights and ratios: spleen, liver, and heart weights normalized to body weight
• Histopathology (H&E): comprehensive examination of bone marrow, spleen, liver, and visceral organs by board-certified veterinary or medical pathologists
• Bone marrow fibrosis grading: reticulin (Gomori silver) and collagen (Masson trichrome) staining with semi-quantitative grading
• Immunohistochemistry: CD41 or von Willebrand factor for megakaryocytes, MPO or Ly6G for myeloid cells, Ter119 and CD71 for erythroid cells, and Ki67 for proliferation
• Flow cytometry: quantification of lineage-positive mature cells and LSK (Lin-Sca1+c-Kit+) stem and progenitor compartments in bone marrow and spleen
• Genotyping and mutant allele burden: allele-specific qPCR or droplet digital PCR on blood, marrow, and spleen DNA

Testing Methods

Genotyping and Allele Burden Quantification

Genomic DNA is extracted from ear punches, peripheral blood, or hematopoietic tissues. Genotyping is performed by PCR amplification across exon 14 of the Jak2 locus followed by Sanger sequencing or allele-specific PCR to confirm the presence of the V617F allele. Mutant allele burden is quantified using allele-specific TaqMan qPCR or droplet digital PCR with mutant and wild-type probe sets, providing sensitivity below 0.1% variant frequency and enabling precise tracking of disease clone dynamics during therapy.

Hematological Analysis

Complete blood counts are acquired on a validated veterinary hematology analyzer with species-specific mouse settings. Automated results are confirmed by manual differential counting of 200 cells on Wright-Giemsa-stained blood smears prepared from fresh blood to correct for platelet and white cell aggregates common in MPN models. Plasma erythropoietin is measured by ELISA, with suppressed levels serving as a functional hallmark of autonomous erythropoiesis.

Histopathology and Fibrosis Scoring

Tissues are fixed in 10% neutral buffered formalin, routinely processed, and embedded in paraffin. Bones are decalcified using EDTA-based methods that preserve antigenicity for immunohistochemistry. Sections cut at 3–4 micrometers are stained with hematoxylin and eosin for routine evaluation. Reticulin fibers are demonstrated by Gomori ammoniacal silver staining and collagen by Masson trichrome, and fibrosis is graded on a semi-quantitative 0–3 scale adapted from the WHO system for human myelofibrosis: grade 0 (no reticulin), grade 1 (focal loose reticulin), grade 2 (diffuse dense reticulin without collagen), and grade 3 (diffuse dense reticulin with collagen bundles and osteosclerosis).

Immunophenotyping

Multiparameter flow cytometry is performed on single-cell suspensions from bone marrow and spleen using antibody panels targeting lineage markers (CD3, B220, Gr-1, Mac-1, Ter119), stem and progenitor markers (Sca-1, c-Kit, CD34, CD150, CD48), and megakaryocytic markers (CD41, CD42b). Immunohistochemistry on paraffin sections provides spatial localization of lineage expansion within tissue architecture. Combined data quantify the degree of myeloid expansion, megakaryocyte burden, and progenitor mobilization characteristic of JAK2 V617F-driven disease.

Applications

JAK2 V617F mouse pathology testing supports a wide range of translational and preclinical research applications:

• Preclinical efficacy evaluation of JAK inhibitors (ruxolitinib, fedratinib, pacritinib) and novel kinase inhibitors, using hematocrit normalization, spleen volume reduction, and fibrosis regression as endpoints
• Pharmacodynamic assessment demonstrating target engagement and JAK-STAT pathway suppression downstream of drug treatment
• Mechanistic studies of MPN initiation, clonal evolution, and progression from polycythemic phase to myelofibrosis
• Evaluation of combination therapies, including hypomethylating agents, interferons, BET inhibitors, and chaperone or apoptotic pathway modulators
• Investigation of thrombotic and inflammatory complications driven by constitutive JAK2 signaling
• Characterization of novel genetically engineered models and validation of disease phenotype prior to interventional studies
• Regulatory-enabling toxicology and efficacy packages supporting IND submissions for hematologic therapeutics

FAQ

At what age do JAK2 V617F mice develop detectable pathology?

Heterozygous Jak2 V617F knock-in mice typically develop erythrocytosis and splenomegaly detectable by 8–12 weeks of age, with disease severity increasing progressively. Homozygous or high-burden mice show earlier onset and more aggressive disease. Reticulin fibrosis generally becomes evident after 12–16 weeks and advances with age, allowing flexible study designs for both early polycythemic and advanced fibrotic stages.

How is disease severity quantified across study groups?

Disease severity is integrated from multiple endpoints: hematocrit and leukocyte counts from CBC, spleen-to-body weight ratio, bone marrow cellularity, megakaryocyte density, semi-quantitative fibrosis grade, and mutant allele burden by ddPCR. Composite scoring combined with blinded histopathology review ensures objective, statistically analyzable comparisons between treatment groups.

Can testing be performed on archived FFPE tissue?

Yes. H&E, reticulin, and trichrome staining, along with validated immunohistochemistry markers, can be performed on formalin-fixed paraffin-embedded samples. Targeted PCR-based allele detection from FFPE-derived DNA is also feasible, although fresh or frozen tissue is recommended for flow cytometry and high-sensitivity allele burden quantification.

What sample sizes and study designs are recommended?

Most efficacy studies enroll 8–12 mice per group with baseline CBC stratification to balance hematocrit across groups. A typical necropsy panel includes terminal CBC, organ weights, and histology of bone marrow, spleen, liver, and major viscera, with flow cytometry and molecular testing performed on parallel cohorts or split samples.

What is the typical turnaround time?

Standard histopathology with fibrosis grading is generally reported within 10–15 working days after sample receipt. Studies incorporating flow cytometry, ddPCR allele burden, and comprehensive pathologist review with pathology peer review typically require 15–25 working days depending on study complexity.